Remedium Capital Partners
Latest statistics and disclosures from Remedium Capital Partners's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002104501
Tip: Access up to 7 years of quarterly data
Positions held by Remedium Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Remedium Capital Partners
Remedium Capital Partners holds 6 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Oruka Therapeutics (ORKA) | 27.3 | $77M | 1.6M | 49.05 |
|
|
| Aeglea Biotherapeutics (SYRE) | 26.1 | $74M | 1.5M | 50.44 |
|
|
| Galecto (DMRA) | 18.8 | $53M | 2.0M | 25.90 |
|
|
| Apogee Therapeutics (APGE) | 17.5 | $49M | 584k | 84.17 |
|
|
| Jade Biosciences (JBIO) | 7.9 | $22M | 1.6M | 14.05 |
|
|
| Crescent Biopharma | 2.4 | $6.6M | 361k | 18.37 |
|
Past Filings by Remedium Capital Partners
SEC 13F filings are viewable for Remedium Capital Partners going back to 2026
- Remedium Capital Partners 2026 Q1 restated filed May 19, 2026
- Remedium Capital Partners 2026 Q1 filed May 13, 2026